<DOC>
	<DOCNO>NCT02392117</DOCNO>
	<brief_summary>This study conduct Europe . The aim non-interventional study investigate safety effectiveness insulin degludec ( Tresiba速 ) real world population type 1 ( T1DM ) 2 ( T2DM ) diabetes mellitus .</brief_summary>
	<brief_title>Investigating Safety Effectiveness Insulin Degludec Real World Population With Type 1 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Informed consent obtain studyrelated activity ( Studyrelated activity procedure relate recording data accord protocol ) Male female patient least 18 year age time inform consent T1DM ( diagnose clinically ) prior inclusion study , and/or T2DM , insulin use patient ( diagnose clinically ) prior inclusion study Planned initiation Tresiba速 Known suspect hypersensitivity Tresiba速 excipients list Section 6.1 SmPC ( Summary Product Characteristics ) relate product Previous participation study ( i.e . provision informed consent ) Patients previously treat Tresiba速 Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>